CytomX Secures Expanded Regeneron Partnership Worth Up to $4 Billion

CytomX Therapeutics and Regeneron Pharmaceuticals have expanded their 2022 oncology collaboration to advance a broader pipeline of conditionally activated bispecific cancer therapies. The amended agreement adds two new development targets and increases the collaboration’s potential value to approximately $4 billion.

The partnership focuses on next-generation T-cell engaging therapies that remain inactive until they reach the tumor microenvironment, where they are selectively activated. This approach may improve the therapeutic window of bispecific immunotherapies while limiting off-target effects.

Financial Terms

Regeneron has nominated two additional targets under the expanded agreement, triggering a $37 million target nomination payment to CytomX. The company also retains the option to nominate up to six additional future targets.

Including target nomination fees and potential preclinical, clinical, regulatory, and commercial milestones, the collaboration could generate up to approximately $4 billion in total payments to CytomX. The company is also eligible to receive tiered royalties on future product sales.

Technology Platforms

The collaboration combines CytomX’s Probody® therapeutic platform with Regeneron’s Veloci-Bi® bispecific antibody technology, part of its broader VelociSuite® platform.

Probody therapeutics use masking technology that keeps antibodies inactive until they encounter proteases that are highly active within tumors. Once activated, the therapies engage their intended targets while reducing activity in healthy tissues.

This conditional activation strategy addresses a key limitation of conventional bispecific antibodies and T-cell engagers, which can cause toxicity when active outside tumors. By restricting activity to cancer tissue, the approach may improve safety while preserving anti-tumor activity.

Strategic Significance

The expanded alliance follows several partnership changes over recent years, including concluded collaborations with Astellas, Bristol Myers Squibb, and Amgen, as CytomX continues to prioritize development of its Probody platform.

CytomX reported approximately $346.7 million in cash, cash equivalents, and short-term investments at the end of the first quarter of 2026 and expects its current resources to fund operations into the second half of 2028. The Regeneron partnership remains one of the company’s most significant strategic collaborations and provides another opportunity to validate its masking technology across multiple therapeutic modalities, including antibody-drug conjugates, cytokines, and T-cell engagers.

Clinical Significance

Regeneron highlighted the complementary strengths of its bispecific antibody expertise and CytomX’s conditional activation technology in advancing novel cancer therapies. CytomX emphasized the role of protease biology and masking technology in expanding the therapeutic potential of immunotherapies while supporting a more selective treatment approach.

Path Foward

Conditionally activated bispecifics are gaining momentum as developers pursue precision immunotherapy strategies that improve efficacy while reducing treatment-related toxicity. By restricting immune activation to the tumor microenvironment, these therapies may broaden the reach of immunotherapy across solid tumors that have historically been difficult to treat.

As additional targets advance through discovery and development, the expanded collaboration positions both companies to build a larger portfolio of conditionally activated bispecific therapies for cancer.

 Reference

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer